Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials
Authors Liu YY, Kou CG, Su YY, Zhang YY, You YY, Zhang LL, Wang MH, Fu YL, Ren XJ, Yang YM
Received 19 March 2017
Accepted for publication 12 May 2017
Published 13 June 2017 Volume 2017:10 Pages 2971—2981
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Samir Farghaly
Yingyu Liu,1 Changgui Kou,1 Yingying Su,1 Yangyu Zhang,1 Yueyue You,1 Lili Zhang,1 Mohan Wang,1 Yingli Fu,1 Xiaojun Ren,2 Yanming Yang2
1Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 2Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin, People’s Republic of China
Objective: The goal of this study was to evaluate the efficacy and safety of modified (accelerated and/or hyperfractionated) radiotherapy in the treatment of esophageal carcinoma, compared with conventional radiotherapy.
Methods: Studies published in the PubMed, Cochrane Library, EMBASE, CBM, VIP, CNKI and Wanfang databases in the most recent two decades were searched for use in this meta-analysis. Only randomized controlled trials were included. The heterogeneity analysis and calculation of the pooled odds ratio (OR) were performed using RevMan 5.3 software. The assessment of publication bias and sensitivity analyses was conducted using Stata 13.0 software.
Results: Twenty trials with a total of 1,742 Chinese patients who met the inclusion criteria were included. The pooled results showed that modified radiotherapy improved the response rate compared with conventional schedules (OR =3.90, 95% confidence interval [CI]: 2.47–6.16, P<0.001). Favorable results were observed for the 1-year (OR =2.58, 95% CI: 2.05–3.26, P<0.001), 3-year (OR =2.30, 95% CI: 1.83–2.89, P<0.001) and 5-year (OR =2.36, 95% CI: 1.74–3.21, P<0.001) overall survival and for the 1-year (OR =2.46, 95% CI: 1.72–3.51, P<0.001), 3-year (OR =2.08, 95% CI: 1.49–2.90, P<0.001) and 5-year (OR =2.15, 95% CI: 1.38–3.34, P<0.001) overall local control rate in the modified fractionation radiotherapy group. However, the altered radiotherapy increased the risk of acute radiation esophagitis (OR =1.70, 95% CI: 1.27–2.28, P<0.001) and acute radiation tracheitis (OR =1.47, 95% CI: 1.09–1.99, P=0.01). No significant differences in the risk of esophageal perforation (OR =1.30, 95% CI: 0.51–3.32, P=0.58) or esophagorrhagia (OR =0.88, 95% CI: 0.41–1.88, P=0.74) were found between the two groups.
Conclusion: Chinese patients with squamous cell esophagus carcinomas gained a significant benefit in terms of the response rate, survival and local control rates from the modified fractionation radiotherapy, but also had an increased risk of acute radiation reactions. Otherwise, there was no observed statistically significant difference in terms of early adverse reactions.
Keywords: esophageal carcinoma, radiotherapy, fractionation, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]